Dry eye syndrome affects women at roughly twice the rate it affects men, and this gap widens after menopause.[1] Many postmenopausal women who develop dry, gritty, or burning eyes assume that restoring estrogen will help. The research shows the opposite may be true.

Understanding why requires understanding which hormones actually regulate tear production.

What Dry Eye Syndrome Is

The tear film is not simply water. It is a three-layer structure: an inner mucous layer, a middle aqueous layer, and an outer lipid layer. The lipid layer, produced by the meibomian glands in the eyelids, prevents the aqueous layer from evaporating between blinks.

When the lipid layer is deficient, the tear film breaks up rapidly, exposing the ocular surface to the air. The result is dryness, irritation, burning, and a foreign body sensation, and paradoxically sometimes excessive reflex tearing, as the eye responds to dryness by producing more aqueous tears that evaporate just as fast.

The most common form of dry eye in postmenopausal women is evaporative, driven by meibomian gland dysfunction rather than insufficient aqueous production. This distinction matters for treatment.

The Androgen Connection

Meibomian glands are androgen-sensitive. Androgen receptors are expressed on meibomian gland cells, and androgens stimulate the synthesis and secretion of the lipids that form the outer tear layer.[2] When androgen levels fall, as they do progressively through midlife, meibomian gland function declines, lipid production decreases, and the tear film becomes unstable.

Low androgen levels are a more significant factor in dry eye disease than low estrogen levels.[2] Women with complete androgen insensitivity syndrome, whose cells cannot respond to androgens, have severe meibomian gland atrophy and dry eye as a characteristic feature. Women with other androgen-deficient states show similar patterns.

Why Estrogen May Worsen Dry Eye

Estrogen inhibits lipid production in sebaceous glands, including the meibomian glands.[2][3] Animal models injected with estrogen show shrinkage and reduced activity of these glands. Epidemiological data in humans show that postmenopausal women on estrogen-containing HRT have higher rates of dry eye symptoms than those not on HRT.

A meta-analysis of randomised trials found that sex hormone replacement therapy (estrogen alone or combined with progestogen) produced limited benefit for dry eye symptoms and in some measures worsened meibomian gland function and tear film stability.[3]

This does not mean HRT is contraindicated for women with dry eye. The other benefits of HRT may outweigh this concern for many women. What it does mean is that HRT should not be expected to improve dry eye, and women who notice worsening symptoms after starting HRT should raise this with their prescriber.

Prevalence and Timing

US epidemiological data find that women over 50 have approximately double the dry eye prevalence of men over 50 (7% versus 4%), with the disparity increasing with age after menopause.[1] The risk is 50–70% higher in women than men overall, with menopause as a clear inflection point.

Onset during perimenopause or early postmenopause is consistent with the hormonal mechanism: androgens decline gradually through midlife, and many women reach the threshold at which meibomian gland function becomes insufficient during this transition.

What Actually Helps

Warm compresses and eyelid hygiene. The first-line approach for evaporative dry eye is physical unblocking of the meibomian glands. A heated eyebag applied for 10–15 minutes liquefies lipid secretions that have solidified or thickened. Gentle eyelid massage following the compress expresses the treated lipid and helps clear gland orifices. Regular practice improves lipid layer quality.

Artificial tears. Preservative-free drops provide symptomatic relief. For evaporative dry eye specifically, lipid-containing formulations may be more effective than aqueous-only drops, since they target the deficient outer tear layer directly.

Omega-3 supplementation. EPA and DHA improve the quality of meibomian secretions. Randomised trials have found that omega-3 supplementation reduces tear evaporation and dry eye symptoms compared to placebo, with effects appearing over several months.[4]

Androgen-based approaches. There is growing evidence for androgen supplementation as a targeted treatment for meibomian gland dysfunction. Topical androgen formulations applied to the eyelid margin and androgen-containing eye drops are in clinical trials and have shown promising early results. This remains investigational.

Humidification and environment. Low-humidity environments (air-conditioned offices, aircraft cabins) accelerate evaporative loss. A humidifier in the bedroom and workplace, and deliberate blinking exercises during screen work, are practical low-risk measures.

When to See an Eye Specialist

Dry eye that does not respond to over-the-counter artificial tears warrants assessment by an ophthalmologist or optometrist with expertise in dry eye. Blepharitis, meibomian gland disease, and other causes of ocular surface disease require specific clinical diagnosis and management.

References

[1] Schaumberg, D. A., Sullivan, D. A., Buring, J. E., Dana, M. R. (2003). Prevalence of dry eye syndrome among US women. American Journal of Ophthalmology, 136(2), 318-326. See also: Dry eye syndrome in menopause and perimenopausal age group. https://pmc.ncbi.nlm.nih.gov/articles/PMC5496280/

[2] Sullivan, D. A., Rocha, E. M., Aragona, P., et al. (2017). TFOS DEWS II sex, gender, and hormones report. The Ocular Surface, 15(3), 284-333. See also: Hormones and dry eye disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC10276676/

[3] Feng, Y., Feng, G., Xu, L., et al. (2019). Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: A meta-analysis of randomized controlled trials. Medicine, 98(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC6200492/

[4] Deinema, L. A., Vingrys, A. J., Wong, C. Y., et al. (2017). A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology, 124(1), 43-52. https://doi.org/10.1016/j.ophtha.2016.09.023